CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: IL17RA (ImmuneEditome ID:23765)

1. Gene summary of enriched editing regions for IL17RA

check button Gene summary
Gene informationGene symbol

IL17RA

Gene ID

23765

GeneSynonymsCANDF5|CD217|CDw217|IL-17RA|IL17R|IMD51|hIL-17R
GeneCytomap

22q11.1

GeneTypeprotein-coding
GeneDescriptioninterleukin-17 receptor A|IL-17 receptor A
GeneModificationdate20230409
UniprotIDQ96F46
PubMed ID

36979355

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr22:17089596-17090189:+ENST00000459971.1ENSG00000177663.12IL17RAncRNA_intronicAluSx3,AluJbchr22:17089596-17090189:+.alignment
chr22:17089596-17090189:+ENST00000477874.1ENSG00000177663.12IL17RAncRNA_intronicAluSx3,AluJbchr22:17089596-17090189:+.alignment
chr22:17110220-17110796:+ENST00000319363.9ENSG00000177663.12IL17RAUTR3L2c,AluJo,AluSzchr22:17110220-17110796:+.alignment
chr22:17110220-17110796:+ENST00000612619.1ENSG00000177663.12IL17RAUTR3L2c,AluJo,AluSzchr22:17110220-17110796:+.alignment
chr22:17113198-17113507:+ENST00000319363.9ENSG00000177663.12IL17RAUTR3AluJbchr22:17113198-17113507:+.alignment
chr22:17113198-17113507:+ENST00000612619.1ENSG00000177663.12IL17RAUTR3AluJbchr22:17113198-17113507:+.alignment


Top

2. Tumor-specific enriched editing regions for IL17RA


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000177663.12,IL17RALUSCEAG3.7455e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for IL17RA


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for IL17RA


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000177663.12,IL17RA
GBMEAGIRENSG00000100201.14chr2238490312:38490436:38492055:38492115-0.32302.3301e-021.0469e-06-0.4253imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000177663.12,IL17RA
GBMEAGIRENSG00000149633.7chr2038217252:38217474:38218243:38218361-0.35701.3800e-032.9062e-07-0.4799imageNADAR;DGCR8;DKC1;EIF4A3;EWSR1;FBL;FUS;HNRNPC;HNRNPL;IGF2BP2;MBNL2;MSI1;RBFOX2;TAF15;TARDBP;U2AF2;UPF1NAT_cells_follicular_helperGSVA_HALLMARK_XENOBIOTIC_METABOLISM
ENSG00000177663.12,IL17RA
THYMEAGA5ENSG00000105518.9chr1911345519:11345737:11346126:11346248:11346007:11346248-0.40781.9561e-025.8057e-05-0.4195imageNADAR;AUH;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TIA1;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NA
ENSG00000177663.12,IL17RA
THYMEAGIRENSG00000168488.14chr1628835932:28836122:28836448:28836485-0.41541.7594e-022.6568e-05-0.4341imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_CD4_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000177663.12,IL17RA
THYMEAGIRENSG00000213983.7chr1423564979:23567319:23567738:235677790.38023.9726e-025.3212e-050.4192imageNAUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184NAT_cells_CD8GSVA_HALLMARK_ANDROGEN_RESPONSE
ENSG00000177663.12,IL17RA
THYMEAGESENSG00000166734.14chr1544380863:44380976:44402886:44403054:44413335:44413436-0.34402.1960e-021.2628e-04-0.4338imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_E2F_TARGETS
ENSG00000177663.12,IL17RA
THYMEAGA3ENSG00000134440.7chr1857621707:57621737:57620568:57620648:57620568:57620651-0.43222.0877e-031.6414e-05-0.4589imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAGSVA_HALLMARK_KRAS_SIGNALING_UP
ENSG00000177663.12,IL17RA
THYMEAGIRENSG00000173442.7chr1165581898:65581965:65583591:65583765-0.35334.4620e-024.1122e-06-0.4761imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000177663.12,IL17RA
THYMEAGIRENSG00000213983.7chr1423564979:23567315:23567738:235677790.40382.1470e-021.8335e-050.4418imageNAUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184NAT_cells_CD4_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000177663.12,IL17RA
THYMEAGA3ENSG00000137103.12chr935853140:35853257:35853979:35854846:35853504:358548460.38063.1682e-022.6378e-060.4818imageNADAR;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LIN28;LIN28A;LIN28B;MBNL2;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;ZNF184TMEM8BT_cells_gamma_deltaGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for IL17RA


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000177663.12,IL17RABLCAEAGMacrophages_M14.6737e-020.2245image
ENSG00000177663.12,IL17RABRCAEAGDendritic_cells_activated1.1535e-020.0923image
chr22:17113198-17113507:+COADEERNK_cells_activated1.8865e-020.3414image
ENSG00000177663.12,IL17RACOADEAGDendritic_cells_activated1.1850e-020.3371image
chr22:17113198-17113507:+DLBCEERB_cells_memory7.9214e-030.5393image
ENSG00000177663.12,IL17RADLBCEAGB_cells_memory1.3891e-030.6262image
ENSG00000177663.12,IL17RAGBMEAGT_cells_regulatory_(Tregs)3.1963e-020.1854image
chr22:17113198-17113507:+HNSCEERPlasma_cells2.6854e-03-0.2612image
ENSG00000177663.12,IL17RAHNSCEAGT_cells_CD81.0281e-020.2097image
ENSG00000177663.12,IL17RAKICHEAGMacrophages_M01.9436e-020.4735image
ENSG00000177663.12,IL17RAKIRCEAGDendritic_cells_resting7.4005e-03-0.1606image
ENSG00000177663.12,IL17RAKIRPEAGNK_cells_activated3.6070e-02-0.2348image
chr22:17089596-17090189:+LAMLEEREosinophils3.8645e-030.3298image
ENSG00000177663.12,IL17RALAMLEAGB_cells_naive1.1516e-020.2244image
ENSG00000177663.12,IL17RALGGEAGT_cells_CD4_memory_activated4.9731e-040.1811image
chr22:17113198-17113507:+MESOEERNK_cells_activated1.2346e-020.3970image
ENSG00000177663.12,IL17RAMESOEAGMast_cells_activated1.6221e-020.3646image
chr22:17110220-17110796:+OVEERB_cells_memory2.4618e-020.1771image
chr22:17113198-17113507:+PAADEERB_cells_memory7.2277e-040.4118image
ENSG00000177663.12,IL17RAPAADEAGB_cells_memory1.0257e-030.3842image
ENSG00000177663.12,IL17RASARCEAGPlasma_cells3.5022e-020.2225image
ENSG00000177663.12,IL17RASKCMEAGT_cells_CD85.3282e-030.1903image
chr22:17110220-17110796:+STADEERMacrophages_M01.3590e-02-0.1547image
ENSG00000177663.12,IL17RASTADEAGT_cells_regulatory_(Tregs)1.3476e-02-0.1467image
ENSG00000177663.12,IL17RATHCAEAGDendritic_cells_activated3.9061e-02-0.1380image
ENSG00000177663.12,IL17RATHYMEAGNK_cells_resting3.5690e-030.3092image


Top

6. Enriched editing regions and immune gene sets for IL17RA


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000177663.12,IL17RADLBCEAG2.4565e-040.69322.3844e-030.60171.7854e-030.61511.2043e-020.5143image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000177663.12,IL17RABLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5032e-020.2727image
ENSG00000177663.12,IL17RABRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.3113e-020.0906image
ENSG00000177663.12,IL17RACOADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG9.4330e-030.3471image
chr22:17113198-17113507:+COADGSVA_HALLMARK_MITOTIC_SPINDLEEER1.5450e-030.4490image
ENSG00000177663.12,IL17RADLBCGSVA_HALLMARK_GLYCOLYSISEAG8.6176e-040.6463image
chr22:17113198-17113507:+DLBCGSVA_HALLMARK_GLYCOLYSISEER2.7828e-050.7581image
ENSG00000177663.12,IL17RAGBMGSVA_HALLMARK_MITOTIC_SPINDLEEAG9.7524e-03-0.2225image
chr22:17113198-17113507:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5046e-020.2128image
ENSG00000177663.12,IL17RAHNSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.7468e-020.1945image
ENSG00000177663.12,IL17RAKICHGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG1.2282e-02-0.5028image
ENSG00000177663.12,IL17RAKIRPGSVA_HALLMARK_ADIPOGENESISEAG7.4268e-040.3695image
chr22:17089596-17090189:+LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.5053e-02-0.2321image
ENSG00000177663.12,IL17RALAMLGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.5964e-02-0.2143image
ENSG00000177663.12,IL17RALGGGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG3.6446e-020.1094image
ENSG00000177663.12,IL17RALUADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG2.6524e-02-0.1450image
chr22:17113198-17113507:+MESOGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.0005e-020.3712image
ENSG00000177663.12,IL17RAMESOGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4072e-020.3719image
chr22:17110220-17110796:+OVGSVA_HALLMARK_MITOTIC_SPINDLEEER5.5774e-05-0.3121image
ENSG00000177663.12,IL17RAOVGSVA_HALLMARK_HEME_METABOLISMEAG1.0528e-020.1862image
ENSG00000177663.12,IL17RAPAADGSVA_HALLMARK_MYC_TARGETS_V2EAG4.2217e-030.3379image
chr22:17113198-17113507:+PAADGSVA_HALLMARK_P53_PATHWAYEER3.2385e-030.3626image
ENSG00000177663.12,IL17RAPRADGSVA_HALLMARK_G2M_CHECKPOINTEAG4.1724e-02-0.1203image
ENSG00000177663.12,IL17RASARCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG4.5875e-020.2110image
ENSG00000177663.12,IL17RASTADGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.3567e-030.1896image
chr22:17110220-17110796:+STADGSVA_HALLMARK_MITOTIC_SPINDLEEER5.5426e-05-0.2502image
ENSG00000177663.12,IL17RATHCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.2758e-02-0.1427image
ENSG00000177663.12,IL17RATHYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.0185e-04-0.3606image
chr22:17113198-17113507:+UCECGSVA_HALLMARK_GLYCOLYSISEER1.7147e-020.4319image
ENSG00000177663.12,IL17RAUCECGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.0187e-02-0.4411image


Top

7. Enriched editing regions and drugs for IL17RA


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000177663.12,IL17RABLCAAZD.2281EAG2.9499e-03-0.3303image
ENSG00000177663.12,IL17RABRCAAxitinibEAG1.9156e-020.0856image
chr22:17113198-17113507:+CESCGSK.650394EER1.4355e-020.2855image
ENSG00000177663.12,IL17RACESCEpothilone.BEAG4.5684e-020.2255image
chr22:17113198-17113507:+COADMetforminEER1.1308e-03-0.4603image
ENSG00000177663.12,IL17RADLBCAxitinibEAG2.5384e-03-0.5988image
chr22:17113198-17113507:+DLBCCCT007093EER1.8176e-050.7688image
ENSG00000177663.12,IL17RAGBMBAY.61.3606EAG4.2913e-050.3457image
chr22:17113198-17113507:+HNSCJNJ.26854165EER3.3322e-02-0.1868image
ENSG00000177663.12,IL17RAHNSCCamptothecinEAG3.4068e-02-0.1738image
ENSG00000177663.12,IL17RAKICHAMG.706EAG2.0649e-05-0.7543image
ENSG00000177663.12,IL17RAKIRPEtoposideEAG8.7387e-030.2914image
chr22:17089596-17090189:+LAMLFTI.277EER3.9680e-03-0.3288image
ENSG00000177663.12,IL17RALAMLGDC.0449EAG3.8179e-03-0.2560image
ENSG00000177663.12,IL17RALGGEmbelinEAG2.6857e-020.1157image
ENSG00000177663.12,IL17RALIHCMG.132EAG3.6938e-020.4111image
ENSG00000177663.12,IL17RALUADAICAREAG1.0647e-020.1667image
ENSG00000177663.12,IL17RALUSCABT.888EAG9.8077e-03-0.1685image
ENSG00000177663.12,IL17RAOVABT.263EAG4.8075e-04-0.2522image
chr22:17110220-17110796:+OVAZD6482EER4.3528e-050.3173image
ENSG00000177663.12,IL17RAPAADIPA.3EAG3.7928e-02-0.2601image
chr22:17113198-17113507:+PAADATRAEER7.4001e-030.3397image
chr22:17113198-17113507:+PCPGCyclopamineEER1.1513e-020.3618image
ENSG00000177663.12,IL17RAPCPGAKT.inhibitor.VIIIEAG2.7901e-020.3021image
ENSG00000177663.12,IL17RAPRADBMS.509744EAG1.1146e-02-0.1496image
ENSG00000177663.12,IL17RASARCCCT018159EAG1.2390e-02-0.2626image
ENSG00000177663.12,IL17RASKCMCyclopamineEAG3.8301e-03-0.1978image
ENSG00000177663.12,IL17RASTADBosutinibEAG2.9333e-03-0.1762image
chr22:17110220-17110796:+STADJNJ.26854165EER3.6368e-03-0.1818image
ENSG00000177663.12,IL17RATGCTLFM.A13EAG2.8426e-020.3556image
ENSG00000177663.12,IL17RATHCAAMG.706EAG9.9149e-04-0.2186image
ENSG00000177663.12,IL17RATHYMEmbelinEAG1.8017e-040.3911image
ENSG00000177663.12,IL17RAUCECAZD6482EAG1.0837e-020.4378image
chr22:17113198-17113507:+UCECAP.24534EER4.6604e-030.5025image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType